Beximco Pharmaceuticals (DHA:BXPHARMA) EV-to-EBIT : 11.10 (As of Apr. 30, 2024)

Beximco Pharmaceuticals EV-to-EBIT Chart

Beximco Pharmaceuticals Annual Data
	Trend	Dec13	Dec14	Dec15	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23
EV-to-EBIT		Get a 7-Day Free Trial					9.42	6.78	12.03	11.06	10.76

Beximco Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															11.77	10.93	11.45	10.76	14.36

Competitive Comparison of Beximco Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beximco Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's EV-to-EBIT falls into.

Beximco Pharmaceuticals EV-to-EBIT Calculation

Beximco Pharmaceuticals's EV-to-EBIT for today is calculated as:

Beximco Pharmaceuticals's current Enterprise Value is BDT58,275 Mil.
Beximco Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT5,252 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals  (DHA:BXPHARMA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Beximco Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Beximco Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was BDT75,417 Mil.
Beximco Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT5,252 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Beximco Pharmaceuticals (DHA:BXPHARMA) Business Description